Diana Alsbrook
University of Tennessee Health Science Center
15 Papers
7 Citations
Diana Alsbrook is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Admission Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker of Outcomes in Large Vessel Occlusion Strokes
Nitin Goyal,Georgios Tsivgoulis,Jason J. Chang,Konark Malhotra,Abhi Pandhi,Muhammad Ishfaq,Diana Alsbrook,Adam S Arthur,Lucas Elijovich,Andrei V. Alexandrov +9 more
TL;DR: Higher admission NLR is an independent predictor of symptomatic intracranial hemorrhage and 3-month mortality in large vessel occlusion patients treated with mechanical thrombectomy, and it may identify a target group for testing adjunctive anti-inflammatory therapies.
135
Neuroinflammation in Acute Ischemic and Hemorrhagic Stroke.
Diana Alsbrook,Mario Di Napoli,Kunal Bhatia,José Biller,Sasan Andalib,Archana Hinduja,Roysten Rodrigues,Miguel Chillón Rodríguez,Sara Y. Sabbagh,Magdy Selim,Maryam Hosseini Farahabadi,Alibay Jafarli,Afshin A. Divani +12 more
TL;DR: Understanding the mechanisms and cellular players involved in neuroinflammation is essential for developing effective therapies to reduce secondary injury and improve stroke outcomes, highlighting the potential for targeting specific cytokines, chemokines, and glial cells as therapeutic strategies.
108
Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines
Kunal Bhatia,Mario Di Napoli,Jeffrey L. Saver,Louise D. McCullough,Maryam Hosseini Farahabadi,Diana Alsbrook,Archana Hinduja,Jorge G. Ortiz Garcia,Sara Y. Sabbagh,Alibay Jafarli,Afshin A. Divani +10 more
TL;DR: The choice between different antiplatelets and anticoagulants for prevention of ischemic stroke depends on the underlying stroke mechanism, cytochrome P450 2C19 polymorphisms, bleeding risk profile, compliance, drug tolerance, and drug resistance.
24
Evaluation of the Safety of Rapid Administration of Undiluted High-Dose Intravenous Levetiracetam
Brittany M Kasturiarachi,Rashi Krishnan,Diana Alsbrook,Brittany Hudson,Hallie R. Kelly,Caitlin E Moran,Khalid Alsherbini,G. Morgan Jones +7 more
TL;DR: Undiluted, rapid administration of IV LEV 1500 mg was well tolerated and safe and included patients ≥ 18 years old that received at least 1 dose of intravenous levetiracetam from January 2018 to February 2021.
6
Impact of Beta-Blockers on Nonhead Injured Trauma Patients.
Leah E. Hendrick,Thomas J. Schroeppel,John P. Sharpe,Diana Alsbrook,Louis J. Magnotti,Jordan A. Weinberg,Benjamin P. Johnson,Richard H. Lewis,L. Paige Clement,Martin A. Croce,Timothy C. Fabian +10 more
TL;DR: In this largest study to date, patients receiving BB were older, more severely injured, and had a higher mortality, unlike TBI patients, multivariable regression showed no benefit from BB in this population of patients.
6